A Critical Review of Samprapti of Madhumeha in Sutrasthana 17 of Charaka Samhita and its Correlation with Type 2 Diabetes Mellitus Pathophysiology
DOI:
https://doi.org/10.47070/ijapr.v14i9.4383Keywords:
Madhumeha, Prameha, Charaka Samhita, Type 2 diabetes mellitus, Insulin resistanceAbstract
Type 2 diabetes mellitus is a major global health burden, and Ayurveda had described a comparable condition, Madhumeha, more than two thousand years earlier. Charaka Samhita, Sutrasthana 17, Sloka 78-81, gives an unusually compact account of Madhumeha's pathogenesis that has drawn less scholarly attention than the fuller description in Nidanasthana. Objectives: This review examines these four Sloka closely, compares them with the treatment of Prameha and Madhumeha in Sushruta Samhita, Ashtanga Hridaya, Madhava Nidana and Sharangadhara Samhita, and builds a stage-by-stage comparison between this classical pathological model and the current understanding of type 2 diabetes mellitus. Methods: A narrative review was conducted following SANRA quality criteria. Classical texts were read in standard published editions. PubMed, Scopus and the DHARA/AYUSH research portal were searched Results: The Sloka describe a sequence of dietary and behavioural excess, tissue vitiation, obstruction of Vāta's channel, depletion of Ojas, a relapsing-remitting course, and complications on neglect. Each stage finds a reasonably specific modern counterpart, from sedentary and caloric risk factors through visceral adiposity to molecular blockade of insulin signalling, progressive beta-cell decline, and diabetic complications. Conclusion: The comparison is strongest at the level of Avarana and weakest for entities like Ojas and Chinta. It is best read as a structured interpretation rather than an established biochemical equivalence, useful for generating hypotheses for further clinical study.
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2026 International Journal of Ayurveda and Pharma Research

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

